Neurosearch A/s

Zealand Pharma A/s

Contera Pharma Aps

Aniona Aps

Jens Damsgaard Mikkelsen

Dan Peters

Gunnar M Olsen

Bjarne Due Larsen

Daniel B Timmermann

John Paul Redrobe

Tino Dyhring

Jeppe Kejser Christensen

Elsebet Østergaard Nielsen

John Bondo Hansen

Elsebet Ostergaard Nielsen

Mikael S Thomsen

Peter G Nielsen

Steven Charles Loechel

Søren Neve

Henrik Björk Hansen

Soren Neve

Mads Kreilgaard

S&oslash;ren Neve

Peter Gudmund Nielsen

Elsebet ØStergaard Nielsen

The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.

Orally available pharmaceutical formulation suitable for improved management of movement disorders

The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.

Exendin variant peptides

This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use

This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use

Peptide agonists of GLP-1 activity

Growing community of inventors

Lyngby, Denmark

Jens Damsgaard Mikkelsen